Epigeneres Biotech: Financial Breakdown
Decoding financial health metrics of Epigeneres Biotech
Total Revenue₹7.4 Cr184%Prev. FY
Total Expenses₹16.6 Cr13%Prev. FY
Profit After Tax₹-17.3 Cr-97%Prev. FY
Total Assets₹38.2 Cr0%Prev. FY
Net Profit Margin-232.7%30%Prev. FY
FAQs on Financials of Epigeneres Biotech
No. In FY25, Epigeneres Biotech reported a net loss of ₹17.3 Cr, so it was not profitable.
Epigeneres Biotech's revenue grew 184.9% year-on-year, from ₹2.6 Cr in FY24 to ₹7.4 Cr in FY25.
Epigeneres Biotech's estimated EBITDA for FY25 was ₹-6.7 Cr, derived from its profit before tax, finance costs, and depreciation & amortisation.
In FY25, Epigeneres Biotech posted revenue of ₹7.4 Cr (up 184.9% YoY) and a net loss of ₹17.3 Cr. Explore the full financials of Epigeneres Biotech here...
Disclaimer
Inc42 Datalabs consolidates intelligence from public records, statutory filings, proprietary research, and vetted third‑party datasets. All information is provided as is—please run your own checks before acting on it. Inc42 Datalabs bears no responsibility for decisions or outcomes based on this data.
Quick Links